Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lorlatinib

FDA-approved product (tablet, oral), marketed as Lorbrena.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lorlatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lymphoma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lorlatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lorlatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

    NCT04127110 · start 2020-11-17

    Registered record
    Registry ID
    NCT04127110
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-11-17
    Completion
    2024-11
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionLorlatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

    NCT04362072 · start 2020-09-29

    Registered record
    Registry ID
    NCT04362072
    Conditions
    Carcinoma; Non-Small-Cell Lung
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-09-29
    Completion
    2024-10-23
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma; Non-Small-Cell Lung
    InterventionLorlatinib
    PhasePhase 4
    Registry statusCompleted

  • Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

    NCT04111705 · start 2020-08-05

    Registered record
    Registry ID
    NCT04111705
    Conditions
    Non Small Cell Lung Cancer Metastatic
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-08-05
    Completion
    2024-12-15
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer Metastatic
    InterventionLorlatinib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

    NCT06282991 · start 2020-07-22

    Registered record
    Registry ID
    NCT06282991
    Conditions
    Non-Small Cell Lung Carcinoma
    Interventions
    Lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-22
    Completion
    2021-01-18
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Carcinoma
    InterventionLorlatinib
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

    NCT03505554 · start 2019-09-28

    Registered record
    Registry ID
    NCT03505554
    Conditions
    Anaplastic Large Cell Lymphoma, ALK-Positive
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-09-28
    Completion
    2025-12-31
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma, ALK-Positive
    InterventionLorlatinib
    PhasePhase 2
    Registry statusCompleted

  • Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

    NCT03737994 · start 2019-07-25

    Registered record
    Registry ID
    NCT03737994
    Conditions
    Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Alectinib; Brigatinib; Carboplatin; Ceritinib; Cisplatin; Crizotinib; Ensartinib; Lorlatinib; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-07-25
    Completion
    2026-03-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    InterventionAlectinib; Brigatinib; Carboplatin; Ceritinib +5 more
    PhasePhase 2
    Registry statusTerminated

  • Study of Lorlatinib in ROS1 Rearranged NSCLC

    NCT03612154 · start 2019-05-02

    Registered record
    Registry ID
    NCT03612154
    Conditions
    Nonsmall Cell Lung Cancer
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-05-02
    Completion
    2023-12-31
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonsmall Cell Lung Cancer
    InterventionLorlatinib
    PhasePhase 2
    Registry statusUnknown

  • A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

    NCT03909971 · start 2019-04-28

    Registered record
    Registry ID
    NCT03909971
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-28
    Completion
    2024-10-21
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionLorlatinib
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

    NCT03727477 · start 2019-02-01

    Registered record
    Registry ID
    NCT03727477
    Conditions
    Non-small Cell Lung Cancer Metastatic; ALK Gene Rearrangement Positive; ROS-1 Gene Rearrangement Positive
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-02-01
    Completion
    2020-10-12
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Metastatic; ALK Gene Rearrangement Positive; ROS-1 Gene Rearrangement Positive
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Lorlatinib Renal Impairment Study

    NCT03542305 · start 2018-08-23

    Registered record
    Registry ID
    NCT03542305
    Conditions
    Renal Impairment
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-08-23
    Completion
    2020-02-20
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionLorlatinib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

    NCT03546894 · start 2018-07-23

    Registered record
    Registry ID
    NCT03546894
    Conditions
    Anaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung
    Interventions
    Brigatinib; Alectinib; Ceritinib; Lorlatinib; Any FDA Approved ALK Inhibitors
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-23
    Completion
    2023-02-13
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung
    InterventionBrigatinib; Alectinib; Ceritinib; Lorlatinib +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

    NCT03126916 · start 2018-05-14

    Registered record
    Registry ID
    NCT03126916
    Conditions
    Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
    Interventions
    Autologous Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Busulfan; Carboplatin; Cisplatin; Computed Tomography; Cyclophosphamide; Dexrazoxane Hydrochloride; Dinutuximab; Doxorubicin Hydrochloride; Echocardiography Test; Etoposide Phosphate; External Beam Radiation Therapy; Iobenguane I-123; Iobenguane I-131; Isotretinoin; Lorlatinib; Magnetic Resonance Imaging; Melphalan Hydrochloride; Multigated Acquisition Scan; Positron Emission Tomography; Sargramostim; Therapeutic Conventional Surgery; Thiotepa; Topotecan Hydrochloride; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-05-14
    Completion
    2030-09-30
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGanglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
    InterventionAutologous Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Busulfan +23 more
    PhasePhase 3
    Registry statusRecruiting

  • NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

    NCT03107988 · start 2017-09-05

    Registered record
    Registry ID
    NCT03107988
    Conditions
    Neuroblastoma
    Interventions
    Lorlatinib; Cyclophosphamide; Topotecan; Filgrastim/pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-05
    Completion
    2025-01-31
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    InterventionLorlatinib; Cyclophosphamide; Topotecan; Filgrastim/pegfilgrastim
    PhasePhase 1
    Registry statusCompleted

  • Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

    NCT03184168 · start 2017-07-05

    Registered record
    Registry ID
    NCT03184168
    Conditions
    Healthy Volunteers
    Interventions
    [14C]lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-07-05
    Completion
    2017-08-25
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Intervention[14C]lorlatinib
    PhasePhase 1
    Registry statusCompleted

  • A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

    NCT03052608 · start 2017-04-27

    Registered record
    Registry ID
    NCT03052608
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Lorlatinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-04-27
    Completion
    2028-12-31
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionLorlatinib; Crizotinib
    PhasePhase 3
    Registry statusActive not recruiting